Key result
LAAO with LARIAT linked to a 0% thromboembolic event rate vs control in high-risk AFib.
Why the study?
Long-term clinical outcomes of left atrial appendage occlusion with the LARIAT device in patients with high risk of stroke and bleeding were not well established.
Does left atrial appendage occlusion with the LARIAT device reduce thromboembolic events and mortality in patients with nonvalvular atrial fibrillation at high risk of stroke and bleeding?
Cohort (n=88)
No
Does left atrial appendage occlusion with the LARIAT device reduce thromboembolic events and mortality in patients with nonvalvular atrial fibrillation at high risk of stroke and bleeding?
Left atrial appendage closure with the LARIAT device significantly reduces thromboembolic events and mortality in high-risk patients with nonvalvular atrial fibrillation.
LAAO with LARIAT linked to fewer thromboembolic events in high-risk AF; leaves open need for RCTs before changing OAC practice.
Backgrounds Left atrial appendage occlusion (LAAO) offers an alternative to oral anticoagulation (OAC) for patients with atrial fibrillation (AF). The aim of this study was to present long‐term clinical outcomes of LAAO in patients with a high risk of stroke and thromboembolic events (CHA2DS2‐VAS‐score ≥ 2) and bleeding (HAS‐BLED score ≥ 2). Material and Methods A prospective, single‐center study was performed in 120 patients who were screened for LAAO with the LARIAT. Out of these 89 patients were underwent LARIAT placement, were 57 had high risk of thromboembolic and bleeding risk (LAA group). Control Group consisted of patients and 31 who screened out from the LARIAT and did not undergo LAAO. Results The mean CHA2DS2‐VAS‐score was 3.6 ± 1.5 versus 3.1 ± 1.2 and HAS‐BLED score was 3.6 ± 1 versus 3 ± 1 compare LAA group versus control group. There were no thromboembolic events in the LAA group. In the control group thromboembolic events were observed in 9.6% (P = 0.017). Annual mortality rate was 1.8% in LAA group and 3.2% in control group (P < 0.05). Estimated bleeding risk reduction in LAA group was 62.2%. Conclusions Long‐term data confirmed that left atrial appendage closure with the LARIAT device is an effective and safe treatment in nonvalvular AF patients with high risk of stroke and bleeding.
No takes yet. Share an insight, caveat, or question.
Litwinowicz et al. (2019) conducted a cohort in Atrial fibrillation (n=88). Left atrial appendage occlusion (LAAO) with LARIAT device vs. Patients who screened out from LARIAT and did not undergo LAAO was evaluated on Thromboembolic events (p=0.017). Left atrial appendage occlusion with the LARIAT device resulted in 0% thromboembolic events compared to 9.6% in the control group (P=0.017) among high-risk patients with atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: